US FDA Authorizes Specific Modified Risk Claim for 20 ZYN Nicotine Pouch Variants.

In a landmark regulatory shift, the U.S. Food and Drug Administration (FDA) has officially issued Modified Risk Tobacco Product (MRTP) orders for 20 ZYN nicotine pouch products. The decision, finalized following an extensive scientific evaluation, marks the first time the American regulator has granted modified risk status to an oral nicotine pouch brand.

The authorizations allow Philip Morris International (PMI) U.S. and its subsidiary, Swedish Match USA, Inc., to market these specific products within the United States using a distinct, science-backed risk reduction claim relative to traditional cigarette smoking.

Authorized Health Claims and Covered Products

Following the issuance of the MRTP orders, the 20 authorized ZYN variants can be marketed in the U.S. with the following explicit statement:

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

The order covers 10 distinct flavor profiles across two standard nicotine strengths (3 mg and 6 mg):

• Flavors Included: Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill, and Menthol.

Regulatory experts emphasize that this authorization is strictly product-specific. It applies only to the 20 reviewed ZYN items and does not extend as a blanket approval for the broader oral nicotine pouch category or other smoke-free brands. These products were previously approved for commercial sale via the FDA’s Premarket Tobacco Product Application (PMTA) pathway in January 2025.

Scientific Evaluation and Public Health Impact

The FDA’s Center for Tobacco Products (CTP) based its decision on a comprehensive review of clinical data, toxicological profiles, population health impacts, and consumer perception studies. The data submitted indicated that switching completely from combustible cigarettes to ZYN significantly reduces a user’s exposure to harmful chemical constituents.

Clinical behavioral studies showed that a substantial portion of adult smokers who transitioned to ZYN successfully reduced or completely eliminated their cigarette consumption. Furthermore, consumer perception testing proved that adult populations accurately understood the relative health claims without misinterpreting the product as entirely risk-free.

Commenting on the milestone, Bret Koplow, Ph.D., J.D., Acting Director of the FDA’s Center for Tobacco Products, stated:

“FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices. This decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products.”

Post-Market Compliance Framework

The MRTP orders are granted for a fixed term of five years and carry stringent post-market surveillance obligations. Swedish Match USA is required to conduct ongoing epidemiological and behavioral studies to track consumer trends.

The FDA retains full authority to withdraw the modified risk designation if post-market monitoring reveals unintended adverse effects, such as a statistically significant rise in youth initiation or fallback behavior among former smokers.